


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7052753/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203). Frontiers in Oncology, 2021, 11, 684867.	2.8	35
2	Neferine increases STI571 chemosensitivity via inhibition of P-gp expression in STI571-resistant K562 cells. Leukemia and Lymphoma, 2011, 52, 694-700.	1.3	11
3	Neferine in the LotusÂPlumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia CellsIn Vitro. Journal of Food Science, 2019, 84, 904-910.	3.1	8
4	Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2020, 38, 4592-4592.	1.6	5
5	Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study Journal of Clinical Oncology, 2021, 39, 306-306.	1.6	1